Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carmen Piccolo

Vascular Surgery Florence, SC Doctor of Osteopathy

NPI 1073826624 CMS profile 3892

101 S Ravenel St, Suite 230, Florence, SC 29506

Open in the dashboard

General payments

$13,591

284 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carmen Piccolo of Florence, SC is reported in the CMS Open Payments database as having received $13,591 across 284 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,998 58
2024 General $2,846 54
2023 General $2,935 37
2022 General $1,324 36
2021 General $719 31
2020 General $1,030 31
2019 General $2,739 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carmen Piccolo
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Carmen Piccolo were reported at $1,998. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Carmen Piccolo Vascular Surgery median Middle half National median
2019 $2,739 $796 $226–$2,363 $163
2020 $1,030 $348 $118–$1,110 $114
2021 $719 $471 $158–$1,421 $132
2022 $1,324 $725 $222–$2,183 $149
2023 $2,935 $836 $257–$2,440 $160
2024 $2,846 $909 $252–$2,619 $164
2025 $1,998 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $3,119 45 payments
  2. Silk Road Medical, Inc. $2,336 11 payments
  3. Endologix, Inc. $2,025 23 payments
  4. Inari Medical, Inc. $1,591 19 payments
  5. Cook Medical LLC $811 25 payments
  6. LeMaitre Vascular, Inc. $383 13 payments
  7. Musculoskeletal Transplant Foundation Inc. $289 3 payments
  8. Cardiovascular Systems Inc. $239 14 payments
  9. Shockwave Medical, Inc $230 10 payments
  10. Janssen Pharmaceuticals, Inc $223 14 payments
  11. Other $2,345 107 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,222 268 payments
  2. Travel and Lodging $4,294 14 payments
  3. Education $76 2 payments
Products named General payments · program years 2019–2025
  1. ENROUTE 0.014 Guidewire $2,314 10 payments
  2. ENROUTE Transcarotid Stent System $2,314 10 payments
  3. ENROUTE Transcarotid Neuroprotection System $2,314 10 payments
  4. ENHANCE Transcarotid Peripheral Access Kit $2,314 10 payments
  5. AFX2 Bifurcated Endograft System $1,766 18 payments
  6. Ovation iX Iliac Stent Graft $1,766 18 payments
  7. FLOWTRIEVER CATHETER, S $1,652 23 payments
  8. GORE TAG Thoracic Endoprosthesis $1,522 5 payments
  9. CT THROMBECTOMY SYSTEM KIT $1,477 15 payments
  10. GORE TAG Thoracic Branch Endoprosthesis $749 9 payments
  11. Other $6,761 269 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

799

Median for Vascular Surgery: 122

Drug cost

$189,473

Median for Vascular Surgery: $14,135

Branded share of claims

59.2%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 74 $80,836
Xarelto Rivaroxaban Brand 63 $57,381
Brilinta Ticagrelor Brand 47 $42,796
Cilostazol Generic 129 $3,620
Clopidogrel Clopidogrel Bisulfate Brand 242 $2,509
Pravastatin Sodium Generic 78 $1,039
Atorvastatin Calcium Generic 45 $462
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 47 $316
Rosuvastatin Calcium Generic 27 $270
Gabapentin Generic 15 $208

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 131 billing codes

Paid by Medicare

$387,952

Medicare's payments for the services billed

Medicare patients

1,432

Average age 75

Services billed

4,310

649 women, 783 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 51%
Diabetes 50%
Chronic kidney disease 44%
Heart failure 32%
COPD 31%
Atrial fibrillation 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

284 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record